168 related articles for article (PubMed ID: 19879210)
1. The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes.
Jessen L; D'Alessio D
Gastroenterology; 2009 Dec; 137(6):1891-4. PubMed ID: 19879210
[No Abstract] [Full Text] [Related]
2. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
[TBL] [Abstract][Full Text] [Related]
3. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
4. [The value of incretin based therapies].
Gallwitz B
Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
[No Abstract] [Full Text] [Related]
5. Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicity.
Fontés G; Hagman DK; Latour MG; Semache M; Poitout V
Diabetes Res Clin Pract; 2010 Mar; 87(3):322-8. PubMed ID: 20092903
[TBL] [Abstract][Full Text] [Related]
6. Incretins: their physiology and application in the treatment of diabetes mellitus.
Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
[TBL] [Abstract][Full Text] [Related]
7. Sitagliptin (Januvia) for type 2 diabetes.
Med Lett Drugs Ther; 2007 Jan; 49(1251):1-3. PubMed ID: 17179897
[No Abstract] [Full Text] [Related]
8. Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes.
Shirakawa J; Amo K; Ohminami H; Orime K; Togashi Y; Ito Y; Tajima K; Koganei M; Sasaki H; Takeda E; Terauchi Y
J Biol Chem; 2011 Jul; 286(29):25467-76. PubMed ID: 21613229
[TBL] [Abstract][Full Text] [Related]
9. [Incretin related agents for treatment of diabetes mellitus].
Miyagawa J; Miuchi M; Nanba M
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):809-16. PubMed ID: 19472544
[No Abstract] [Full Text] [Related]
10. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
Aaboe K; Akram S; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2015 Jan; 17(1):74-81. PubMed ID: 25243647
[TBL] [Abstract][Full Text] [Related]
11. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
12. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.
Verspohl EJ
Pharmacol Ther; 2009 Oct; 124(1):113-38. PubMed ID: 19545590
[TBL] [Abstract][Full Text] [Related]
13. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
Winkler G
Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
[TBL] [Abstract][Full Text] [Related]
14. A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice.
Perry RA; Craig SL; Gault VA; Flatt PR; Irwin N
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34370015
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide: the therapeutic promise from animal models.
Knudsen LB
Int J Clin Pract Suppl; 2010 Oct; (167):4-11. PubMed ID: 20887299
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of incretin based therapies: clinical trial data.
White J
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S30-40. PubMed ID: 19801363
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.
Holst JJ
Diabetologia; 2006 Feb; 49(2):253-60. PubMed ID: 16416146
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
